Bayer files for second regorafenib use in Japan, GIST
This article was originally published in Scrip
Executive Summary
Bayer is wasting no time in expanding the planned indications for regorafenib in Japan, filing an approval application for use in metastatic and/or unresectable gastrointestinal stromal tumors (GIST) within six months of that for colorectal cancer.